Exosome Targeting Services at Creative Biolabs Ready to Boost Drug Delivery Research
Creative Biolabs updates the custom services of exosome targeting, covering exosome display and targeting exosome lentivirus vector construction, to escalate the development of nanoparticles for drug delivery and vaccine design.
Exosomes are picking up steam among scientists because they can perform a role in the immune response, antigen presentation, cell migration, cell differentiation, and tumor invasion. Exosomes, which provide a mechanism for macromolecules to be exchanged between cells, play a part in the development of various illnesses, particularly in the modulation of the cancer microenvironment and immune response.
Recently, several studies have shown that exosomes express some lipids and cell adhesion molecules and ligands naturally targeting certain types of recipient cells, which suggests that exosomes have natural targeting ability based on donor cells and can act as an efficient tool for targeting delivery. With years of experiences in exosome technology, Creative Biolabs has combined the delivery capabilities of exosomes with targeting technology and biomolecular engineering approaches, and now offers the custom services of exosome targeting to escalate the development of nanoparticles for drug delivery and vaccine design.
Creative Biolabs' scientific team is adept in using exosome display technology for a variety of research and applications. Exosome display technology could be used to create antibodies against a variety of targets, including G protein-coupled receptors (GPCRs). Moreover, exosome display offers a handy platform for displaying membrane proteins in their native conformation and environment, and recombinant exosomes containing potential therapeutic targets may be utilized to screen cognate ligands or small molecules.
Research has also found that exosome targeting can be achieved by the construction of a lentivirus vector and scientists at Creative Biolabs have developed an exosome targeting peptide for interested proteins fusion, producing lentivectors that are able to deliver the interested proteins into exosomes.
“With the help of a professional expert team and cutting-edge technologies for exosome targeting, we can now provide custom exosome therapy development services with the best quality and the most competitive price. Our team has helped clients successfully accelerate their projects and will continue to learn from the experience to provide better services to future partners.” as introduced a scientist at Creative Biolabs.
Further information on exosome-related services and products at Creative Biolabs can be found on https://www.creative-biolabs.com/exosome.
About Creative Biolabs
Empowered by leading technology and years of experience in biomedical science, Creative Biolabs focuses on offering a full range of exosome-related services and products. The comprehensive services include exosome purification, sampling, analysis, manufacturing, and exosome-based application. The high-quality exosome products involve all aspects of exosome research, such as exosome isolation tools, identification kits, and related antibody.
Related news
-
Lonza Extends Collaboration with Major Biopharmaceutical Partner for Large-Scale Monoclonal Antibody Commercial Supply
Ad Hoc Release Pursuant to Art. 53 Listing Rules Long-term collaboration for commercial supply of monoclonal antibodies will complete the integrated supply chain for the manufacture of an antibody-drug conjugate (ADC) for use against hard-to-treat cancers The deal enables the customer to access commercial-scale production of all elements of its ADC at one site, ensuring security of supply and delivering significant economies of scale. It demonstrates the value of Lonza’s Ibex® Solutions, providing...
-
Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced the publication of preclinical data in the peer-reviewed journal Cancer Immunology, Immunotherapy, for its lead clinical oncology program, RTX-240, for the treatment of adults with advanced solid tumors and relapsed/refractory acute myeloid leukemia. The paper entitled “Ant...
-
Microbiotica`s Live Bacterial Therapeutic, MB097, in development to begin clinical trials in 2022 in immuno-oncology
MB097 is a consortium of bacteria at the core of the microbiome signature predictive of patient response to Immune Checkpoint Inhibitor therapy Data show potent anti-tumour efficacy in vivo and in vitro MB097 is in manufacturing process development for Ph1b study expected to start next year MB097 is the first microbiome precision medicine in immuno-oncology, clinically designed in the same patient cohort in which it will be tested Cambridge, UK, 23 June 2021 – Microbiotica, a leading player in...
-
MagForce AG Supports World Brain Tumor Day and Informs about Various Patient Events to Raise Awareness for One of the Deadliest Oncological Indications
MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, offering the NanoTherm Therapy System for the treatment of brain tumors, supports World Brain Tumor Day on June 8th, 2021 and informs about various virtual patient events to raise awareness for this devastating disease. “Though rare compared to other types of cancers, brain tumors, especially glioblastomas, are a devastating and mostly fatal disease. Despite...
-
Creative Biolabs Upgrades Oncolytic Virus Product List for Immunotherapy Research
As early as around 1800, doctors discovered that certain cancer patients would have their symptoms reduced after being briefly infected with viruses. With the advancement of genetic engineering technology, the idea that viruses have the potential to improve and mediate immunotherapy has been established. Oncolytic viruses (OVs) are such kind of viruses that can replicate in tumor tissues, and kill tumor cells. Up to now, two OV drugs have been marketed globally, and many more are still in the research and developme...
Customer comments
No comments were found for Exosome Targeting Services at Creative Biolabs Ready to Boost Drug Delivery Research. Be the first to comment!